Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
Should You Retain Tempus AI Stock In Your Portfolio Now?
Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms
Tempus AI: AI Precision Medicine With A Moat
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy
Tempus AI: A Unique AI Business Model With Asymmetric Upside
Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing
Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
Why Is Tempus (TEM) Down 11.2% Since Last Earnings Report?
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
AI News You Need to Know — June Edition: Capex, Inference, & Beyond
Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
Consumer Tech News (May 25-29): Dell, IBM, CrowdStrike, Meta Lead Big Tech AI Push
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
Tempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
Tempus Introduces ‘Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology
Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology
HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Tempus AI: Taking Advantage Of Investor Myopia
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use
4 Heavily Shorted AI Stocks to Watch Right Now
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
3 Stocks Poised to Disrupt the Healthcare Market by 2030
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
Tempus AI: Another Post-Earnings Dip Worth Buying
TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript
Tempus AI (TEM) Reports Q1 Loss, Beats Revenue Estimates
Tempus Reports First Quarter 2026 Results
Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?